Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Breakthrough Bleeds Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support ICD-10 Codes for Rare Bleeding Disorders
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
Congenital Hemophilia with Inhibitors
Congenital Hemophilia with Inhibitors
  • Overview
  • Clinical Pathway

Managing inhibitors is important for patient health

Managing inhibitors is important for patient health

Actor portrayal

managinginhibitors

Patients with hemophilia A or B may develop inhibitors, which are IgG alloantibodies to exogenous clotting factor VIII (FVIII) or factor IX (FIX) that neutralize the function of infused clotting factor concentrates (CFCs). Inhibitors are present more frequently in patients with severe hemophilia.1

Occurrence of inhibitors in hemophilia patients

Hemophilia A

Hemophilia A

Occurrence of inhibitors in patients with hemophilia A statistic

Hemophilia B

Hemophilia B

Occurrence of inhibitors in patients with hemophilia B statistic

aAmong previously untreated patients

Actor portrayal

Risk factors for inhibitor formation in hemophilia A1

Severity of disease

Family history of inhibitors

Black African ancestry

Hispanic ancestry

Genetic variants 

High-intensity factor exposure

Importance of detecting and managing inhibitors

According to guidelines from the World Federation of Hemophilia (WFH), controlling bleeds in patients with inhibitors is more challenging—making early identification and careful management of inhibitors crucial to patient health.1

The WFH recommends testing patients with hemophilia A or B for inhibitors:
  • After the initial factor exposure
  • After intensive factor exposure, e.g., daily exposure for more than 5 days 
  • When a patient experiences recurrent bleeds or target joint bleeds, despite adequate CFC replacement therapy 
  • Upon failure to respond to adequate CFC replacement therapy 
  • After lower than expected factor recovery or half- life after CFC replacement therapy 
  • Upon suboptimal clinical or laboratory response to CFC replacement therapy 
  • Before surgery 
  • Upon suboptimal post-operative response to CFC replacement therapy
Review additional WFH inhibitor screening recommendations

CFC=clotting factor concentrate.
(Content above adapted from World Federation of Hemophilia guidelines and used with permission.)

Inhibitors to FVIII or FIX are associated with a higher disease burden, including increased risk of musculoskeletal complications, pain, physical limitations, and treatment challenges.1

– WFH Guidelines for the Management of Hemophilia

Actor portrayal

CHwI patients are 2x as likely to be hospitalized for a bleeding complication2

Explore a clinical pathway

See the common steps for treating emergent bleeds in patients with CHwI.

Get started
Pathway icon

Actor portrayal

Learn about MASAC recommendations for CHwI

The National Hemophilia Foundation’s Medical and Scientific Advisory Council (MASAC) guidelines address key areas of hemophilia management, including for patients with inhibitors.

Find out more

References:

  1. World Federation of Hemophilia. Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158.
  2. Centers for Disease Control and Prevention. Hemophilia. https://www.cdc.gov/ncbddd/hemophilia/inhibitors.html. September 6, 2018. Accessed April 22, 2021.
Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Breakthrough Bleeds
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support
      ICD-10 Codes for Rare Bleeding Disorders

novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to pro.novonordisk.com.

Terms of Use | Privacy Notice | Consumer Health Privacy Notice | Cookie Notice | Privacy Request | Contact Us |
novonordisk-us.com    
© 2023 Novo Nordisk All rights reserved. US23HCP00056 August 2023

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials